Medicare should cover GLP-1 drugs for all adults with obesity

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Medicaid, Medicare, ACA, NHS, insurance coverage, prior authorization, healthcare workforce, and access disparities.

Medicare Part B/D, Medicare Advantage, IRA drug negotiations, 340B, most-favored-nation pricing, and federal drug pricing policy.

Medicaid cuts, funding freezes, state waivers, directed payments, CHIP, and state-level healthcare access policies.

Medical debt, out-of-pocket costs, voter concerns, racial disparities, rural access, and international healthcare access.

Nurse shortages, telehealth expansion, NHS workforce, hospital consolidation, and psychiatric care access.

ACA enrollment, premiums, marketplace cancellations, Essential Plan, uninsured rate, and insurance regulation.

GLP-1 drug durability, eligibility, medications, long-term risks, effectiveness, and drug side effects.